Literature DB >> 24126578

New 2-thiopyridines as potential candidates for killing both actively growing and dormant Mycobacterium tuberculosis cells.

Elena Salina1, Olga Ryabova, Arseny Kaprelyants, Vadim Makarov.   

Abstract

From in vivo observations, a majority of M. tuberculosis cells in latently infected individuals are in a dormant and probably nonculturable state, display little metabolic activity, and are phenotypically resistant to antibiotics. Despite many attempts, no specific antimicrobials effective against latent tuberculosis have yet been found, partly because of a lack of reliable and adequate in vitro models for screening of drug candidates. We propose here a novel in vitro model of M. tuberculosis dormancy that meets the important criteria of latency, namely, nonculturability of cells, considerable reduction of metabolic activity, and significant phenotypic resistance to the first-line antibiotics rifampin and isoniazid. Using this model, we found a new group of 2-thiopyridine derivatives that had potent antibacterial activity against both actively growing and dormant M. tuberculosis cells. By means of the model of M. tuberculosis nonculturability, several new 2-thiopyridine derivatives were found to have potent antitubercular activity. The compounds are effective against both active and dormant M. tuberculosis cells. The bactericidal effects of compounds against dormant M. tuberculosis was confirmed by using three different in vitro models of tuberculosis dormancy. The model of nonculturability could be used as a reliable tool for screening drug candidates, and 2-thiopyridine derivatives may be regarded as prominent compounds for further development of new drugs for curing latent M. tuberculosis infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24126578      PMCID: PMC3910762          DOI: 10.1128/AAC.01308-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

Review 1.  Drugs for bad bugs: confronting the challenges of antibacterial discovery.

Authors:  David J Payne; Michael N Gwynn; David J Holmes; David L Pompliano
Journal:  Nat Rev Drug Discov       Date:  2006-12-08       Impact factor: 84.694

2.  Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.

Authors:  Claudia Sala; Neeraj Dhar; Ruben C Hartkoorn; Ming Zhang; Young Hwan Ha; Patricia Schneider; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2010-08-02       Impact factor: 5.191

3.  Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide.

Authors:  Y Hu; J A Mangan; J Dhillon; K M Sole; D A Mitchison; P D Butcher; A R Coates
Journal:  J Bacteriol       Date:  2000-11       Impact factor: 3.490

4.  Synthesis and antileprosy activity of some dialkyldithiocarbamates.

Authors:  Vadim Makarov; Olga B Riabova; Anatoly Yuschenko; Nailya Urlyapova; Adilya Daudova; Peter F Zipfel; Ute Möllmann
Journal:  J Antimicrob Chemother       Date:  2006-04-04       Impact factor: 5.790

Review 5.  Letting sleeping dos lie: does dormancy play a role in tuberculosis?

Authors:  Michael C Chao; Eric J Rubin
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

6.  Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.

Authors:  J Dhillon; J M Dickinson; K Sole; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

7.  Energy production genes sucB and ubiF are involved in persister survival and tolerance to multiple antibiotics and stresses in Escherichia coli.

Authors:  Chao Ma; Shuzhen Sim; Wanliang Shi; Lijun Du; Dongming Xing; Ying Zhang
Journal:  FEMS Microbiol Lett       Date:  2009-11-17       Impact factor: 2.742

8.  Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability.

Authors:  Martin Gengenbacher; Srinivasa P S Rao; Kevin Pethe; Thomas Dick
Journal:  Microbiology       Date:  2009-10-01       Impact factor: 2.777

9.  A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen.

Authors:  Chirajyoti Deb; Chang-Muk Lee; Vinod S Dubey; Jaiyanth Daniel; Bassam Abomoelak; Tatiana D Sirakova; Santosh Pawar; Linda Rogers; Pappachan E Kolattukudy
Journal:  PLoS One       Date:  2009-06-29       Impact factor: 3.240

10.  Mycobacterium tuberculosis from chronic murine infections that grows in liquid but not on solid medium.

Authors:  Jasvir Dhillon; Douglas B Lowrie; Denis A Mitchison
Journal:  BMC Infect Dis       Date:  2004-11-17       Impact factor: 3.090

View more
  12 in total

1.  Mechanism of resistance to an antitubercular 2-thiopyridine derivative that is also active against Burkholderia cenocepacia.

Authors:  Viola C Scoffone; Francesca Spadaro; Claudia Udine; Vadim Makarov; Marco Fondi; Renato Fani; Edda De Rossi; Giovanna Riccardi; Silvia Buroni
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

Review 2.  Targeting Phenotypically Tolerant Mycobacterium tuberculosis.

Authors:  Ben Gold; Carl Nathan
Journal:  Microbiol Spectr       Date:  2017-01

3.  Machine Learning Models for Mycobacterium tuberculosis In Vitro Activity: Prediction and Target Visualization.

Authors:  Thomas R Lane; Fabio Urbina; Laura Rank; Jacob Gerlach; Olga Riabova; Alexander Lepioshkin; Elena Kazakova; Anthony Vocat; Valery Tkachenko; Stewart Cole; Vadim Makarov; Sean Ekins
Journal:  Mol Pharm       Date:  2021-12-29       Impact factor: 5.364

4.  In Vitro Activity of 3-Triazeneindoles against Mycobacterium tuberculosis and Mycobacterium avium.

Authors:  Boris V Nikonenko; Albert Kornienko; Konstantin Majorov; Pavel Ivanov; Tatiana Kondratieva; Maria Korotetskaya; Alexander S Apt; Elena Salina; Valeriya Velezheva
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

5.  Potassium availability triggers Mycobacterium tuberculosis transition to, and resuscitation from, non-culturable (dormant) states.

Authors:  Elena G Salina; Simon J Waddell; Nadine Hoffmann; Ida Rosenkrands; Philip D Butcher; Arseny S Kaprelyants
Journal:  Open Biol       Date:  2014-10       Impact factor: 6.411

6.  Benzoylphenyl thiocyanates are new, effective inhibitors of the mycobacterial resuscitation promoting factor B protein.

Authors:  Galina R Demina; Vadim D Nikitushkin; Margarita O Shleeva; Olga B Riabova; Alexander Yu Lepioshkin; Vadim A Makarov; Arseny S Kaprelyants
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-11-02       Impact factor: 3.944

7.  Protein Composition of Mycobacterium smegmatis Differs Significantly Between Active Cells and Dormant Cells With Ovoid Morphology.

Authors:  Kseniya Trutneva; Margarita Shleeva; Vadim Nikitushkin; Galina Demina; Arseny Kaprelyants
Journal:  Front Microbiol       Date:  2018-09-04       Impact factor: 5.640

8.  Resuscitation of Dormant "Non-culturable" Mycobacterium tuberculosis Is Characterized by Immediate Transcriptional Burst.

Authors:  Elena G Salina; Artem S Grigorov; Oksana S Bychenko; Yulia V Skvortsova; Ilgar Z Mamedov; Tatyana L Azhikina; Arseny S Kaprelyants
Journal:  Front Cell Infect Microbiol       Date:  2019-07-30       Impact factor: 5.293

9.  Dormant non-culturable Mycobacterium tuberculosis retains stable low-abundant mRNA.

Authors:  Dmitriy V Ignatov; Elena G Salina; Mikhail V Fursov; Timofey A Skvortsov; Tatyana L Azhikina; Arseny S Kaprelyants
Journal:  BMC Genomics       Date:  2015-11-16       Impact factor: 3.969

10.  Development of an In Vitro Assay for Detection of Drug-Induced Resuscitation-Promoting-Factor-Dependent Mycobacteria.

Authors:  Jessica Loraine; Feifei Pu; Obolbek Turapov; Galina V Mukamolova
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.